Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in HSCT Recipients (INMUNOEND): a Protocol for a Prospective, Observational, Multicenter Study

NCT06814301 is registered in ClinicalTrials.gov with Maimónides Biomedical Research Institute of Córdoba as lead sponsor.

NCT NCT06814301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06814301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in HSCT Recipients (INMUNOEND): a Protocol for a Prospective, Observational, Multicenter Study
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
September 30, 2027
Enrollment
123 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus cell mediated immunity, stem cell transplantation, hematopoietic